Merck's antipsychotic Saphris is tied to hypersensitivity, FDA says

09/1/2011 | Medscape (free registration)

Merck & Co.'s atypical antipsychotic Saphris, or asenapine maleate, is associated with serious allergic reactions, including angioedema and anaphylaxis, according to an FDA alert. The agency's Adverse Event Reporting System lists 52 hypersensitivity cases among Saphris users, with some reactions occurring simultaneously or after the first dose.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Claims Director
PacificSource
Springfield, OR
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA